Searchable abstracts of presentations at key conferences in endocrinology

ea0044p66 | Clinical biochemistry | SFEBES2016

Audit of plasma catecholamines vs. plasma metanephrines: experience at a tertiary endocrine referral centre

Taylor David R , Alexander Alex , Schweitzer Adam , Stone Colin , Whitelaw Ben , Aylwin Simon , Vincent Royce P

Background: Phaeochromocytoma and paraganglioma (PPGLs) are rare neuroendocrine tumours arising from the adrenal medulla and paraganglia. Biochemical assessment relies on demonstrating elevated concentrations of catecholamines and their metabolites. Analytical methods for catecholamine and metanephrine measurement vary in sensitivity and specificity. We reviewed our biochemical work-up in order to optimise patient diagnosis.Methods: This retrospective au...

ea0044p79 | Clinical biochemistry | SFEBES2016

Immunoassay cortisol day curve dangerously overestimates cortisol reserve in a metyrapone treated patient

Leong Christine H M , Taylor David R , Gilbert Jackie , Whitelaw Benjamin C

Background: Metyrapone is commonly used in medical management of Cushing’s syndrome. It inhibits 11-β hydroxylase, which catalyses the conversion of 11-deoxycortisol to cortisol. The adequacy of metyrapone blockade can be assessed either clinically or biochemically using a target mean serum cortisol 150–300 nmol/l. Cortisol is normally measured by immunoassay.Case report: A 21-year-old female presented with clinical and biochemical feature...

ea0044p80 | Clinical biochemistry | SFEBES2016

Cortisol measurement using immunoassay versus liquid chromatography-tandem mass spectrometry: metyrapone dose-related discrepancies in cortisol values

Leong Christine H M , Taylor David R , Whitelaw Benjamin C , Aylwin Simon

Background: Metyrapone inhibits 11-β hydroxylase and causes a subsequent rise in the cortisol precursor, 11-deoxycortisol. Cortisol measurements by immunoassays are susceptible to interference and reagent antibody cross-reactivity with cortisol precursors when used in patients receiving metyrapone treatment. Clinicians rely on clinical and biochemical features of cortisol excess for dose titration of this medical blockade. The extent of this interference remains unclear. ...

ea0044p8 | Adrenal and Steroids | SFEBES2016

Full characterisation of adrenal steroidogenesis by liquid-chromatography–mass spectrometry (LC–MS/MS) in metyrapone and/or ketoconazole-treated pituitary/adrenal Cushing’s

Taylor David R , Leong Christine H M , Bhatt Aagna E , Ghataore Lea , Aylwin Simon , Whitelaw Ben , Vincent Royce P

Introduction: Pituitary and adrenal Cushing’s may be managed by pharmacological-inhibition of adrenal steroidogenesis, using metyrapone and/or ketoconazole. Assessment of biochemical control is challenging owing to cross-reactivity in immunoassays (e.g. cortisol and 11-deoxycortisol) leading to over/under-treatment. Off-target effects can also result, e.g. hyperandrogenism/mineralocorticoid hypertension (increased 11-deoxycorticosterone/DOC). LC-MS/MS analysis is free fro...

ea0056p41 | Adrenal cortex (to include Cushing's) | ECE2018

Outcomes of patients undergoing surgery for primary aldosteronism based on adrenal venous sampling and/or radiological lateralisation indicate a role for both modalities in case selection

Davis Lauramay , Lewis Dylan , Clough Jennifer , Whitelaw Benjamin C , Gilbert Jackie , Diaz-Cano Salvador , Taylor David R , Vincent Royce P , Hubbard Jonathan , Galata Gabriele , Schulte Klaus-Martin , Aylwin Simon J B

Background: Adrenal venous sampling (AVS) is considered the gold standard for lateralisation of aldosterone production in patients with primary aldosteronism (PA). However, in some patients AVS is not technically successful and management may depend on radiological findings.Aim: To determine 1) the success rate of AVS and 2) the outcomes after surgery related to the lateralisation modality.Method: 156 patients were included who pre...

ea0056p140 | Endocrine tumours and neoplasia | ECE2018

Achievement of therapeutic mitotane concentrations in management of advanced adrenocortical cancer: a single centre experience in 47 patients

Bakhit Mohamed , Whitelaw Benjamin C , Gilbert Jackie , Coskeran Patsy , Diaz-Cano Salvador , Taylor David R , Taylor Norman T , Ghatore Lea , Lewis Dylan , Vivian Gillian , Sarker Debashis , Ross Paul , Davis Laura May , Clough Jennifer , Hubbard Johnathan G , Galata Gabriele , Prachalias Andreas , Schulte Klaus-Martin , Aylwin Simon J B

Introduction: Multi-modal therapy for adrenocortical carcinoma (ACC) includes surgery, therapy with the adrenolytic agent mitotane and systemic chemotherapy. Achievement of therapeutic mitotane concentrations (≥14 mg/l) has been related to improved outcomes.Aim: To evaluate the effectiveness of a defined* high dose protocol mitotane therapy in patients with advanced ACC (stages III and IV).Methods: Review of patients presenti...